Premium
[O3–03–04]: AV1451‐PET UPTAKE AND CSF BIOMARKERS IN A HETEROGENEOUS CLINICAL SAMPLE: TWO SIDES OF THE SAME COIN?
Author(s) -
La Joie Renaud,
Bejanin Alexandre,
Fagan Anne M.,
Ayakta Nagehan,
Baker Suzanne L.,
Bourakova Viktoriya,
Karydas Anna,
Jerome Gina,
O'Neil James P.,
Pham Julie,
Visani Adrienne,
Rosen Howard J.,
Boxer Adam L.,
Miller Bruce L.,
Jagust William J.,
Rabinovici Gil D.
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.07.317
Subject(s) - cerebrospinal fluid , medicine , nuclear medicine , pathology , oncology
to established brain-behavior relationships (Figure 1). This pattern of regional associations remained essentially unchanged – although less spatially extended – when gray matter volume or C-PiB uptake maps were added as covariates (Figure 2). Mediation analyses revealed both direct and gray matter-mediated effects of F-AV1451 uptake on cognitive performance (Figure 3). Conclusions: Tau pathology is related in a region-specific manner to cognitive impairment in AD. These regional relationships are weakly related to amyloid burden, but are in part mediated by graymatter volumes. These results suggest that tau pathology may lead to cognitive deficits through a variety of mechanisms, including, but not restricted, to neuronal loss.